The bumps come as the Drug Enforcement Administration continues to draft a rule that will place new restrictions on how health professionals can use telemedicine to prescribe highly regulated drugs like ketamine.
Ketamine has been used in hospital anesthesia for decades and illegally as a companion drug. In recent years, it has shown promise in treating depression when traditional antidepressants have failed.
The FDA approved a derivative of ketamine, the nasal spray Spravato, in 2019. But the strict rules surrounding the use of Spravato have led many people to seek other ways to get the drug that are legal but not FDA-approved. Clinics have been set up to offer infusions, while some providers prescribe a tablet that can be taken at home.
Ketamine’s rapid spread from health care facilities to patients’ homes has fueled debate among ketamine providers, who see the drug as an important tool in the fight against mental illness but disagree about its use.
This is a wake-up call for ketamine practitioners and the broader medical community to set clear and consistent safeguards guided by real data and medicine, the nonprofit American Society of Ketamine Physicians, Psychotherapists and Practitioners said after ketamine was implicated in Perry’s death. The group promised to prepare guidelines for the use of ketamine at home.
Ketamine is considered safe by many doctors and has less abuse potential than opioids. However, the FDA has not established dosage guidelines for ketamine when used for psychiatric conditions, and the agency reports safety concerns that include abuse, increased blood pressure, and bladder problems. According to the FDA, the risk is increased if the medicine is used at home without a healthcare provider.
Despite such alarms, there is great excitement about the potential of ketamine and other drugs with psychedelic properties to treat mental disorders. Barely two weeks after the FDA warning, psychedelic-focused private equity firm Beckley Waves acquired telehealth ketamine company Nue Life for undisclosed terms. According to data provider PitchBook, Nue Life was valued at $103 million in 2022. Competing company Mindbloom was estimated to be worth $230 million in 2021, according to the service.
According to the contract announcement, Nue Life has provided home ketamine treatment to more than 10,000 patients in 23 states. Daniel Love, founder of Beckley Waves, said through Nue Life, we can provide affordable access to safe and legal ketamine treatment, adding that the company takes the risks seriously and is committed to strengthening safety protocols.
This doctor is prescribing ketamine to thousands online. Everything is legal.
One big difference between ketamine doctors is how and where patients receive treatment. One camp argues that the drug is safest and most effective when used in the presence of a trained therapist, while others argue that allowing patients to use it at home can provide more affordable relief from depression, anxiety and post-traumatic stress disorder.
Each approach has trade-offs. An on-site trained Therapist can help the patient navigate the mind-altering effects of drugs and ensure physical safety, but it can be expensive. Signing up for a virtual service may be easier for some, although it doesn’t include the same level of support as an in-person experience.
Raquel Bennett, a ketamine expert and founder of the Kriya Institute, belongs to the former camp and sees ketamine as a tool for self-discovery. The goal of ethical ketamine treatment is not to make clients dependent on ketamine forever, he said, adding that if doctors don’t help patients learn new emotional skills, they could be contributing to ketamine addiction.
A spokesperson for Mindbloom said it has helped thousands of people overcome depression and anxiety and that its protocols include comprehensive safeguards to ensure the treatment is effective and safe.
The debate over ketamine use at home intensified during the pandemic, as Mindbloom, Nue Life and other startups benefited from a federal waiver of a requirement that prescribers personally evaluate patients before treating them with the DEA-regulated drug. This meant that doctors could prescribe ketamine to patients from their computers, often treating people in multiple states.
In March, the DEA proposed a rule on how healthcare professionals use telehealth to prescribe drugs containing controlled substances, which are considered to be of varying degrees of abuse. For drugs classified as ketamine, a doctor could prescribe a 30-day course of medication during a telehealth visit, but after that the patient must be evaluated in person to continue the treatment.
That prompted an avalanche of backlash from patients and providers who have come to rely on telehealth for controlled drugs, from Adderall to benzodiazepines. Many said that ketamine has saved their lives. The DEA received more than 38,000 comments on the proposed telemedicine rule and the related buprenorphine rule.
“We believe it’s one of the largest comments we’ve received in the history of the DEA,” agency administrator Anne Milgram said at a hearing in September.
Not all advocates of expanding access to telehealth believe ketamine should be part of it. At a September listening session, Talkiatry Chief Medical Officer Georgia Gaveras proposed excluding ketamine from the telehealth rule, noting that patients using Spravato must be under the supervision of a healthcare professional.
We also believe that there are also very significant withdrawal risks in prescribing a substance that holds great promise for depression at home, and we believe that it should be regulated more, he said, according to the minutes of the event.
Some pharmaceutical companies are betting that they can cure generic ketamine, which is prescribed elsewhere than today.
Adam Kaplin saw the power of ketamine while overseeing the clinical trials that led to Spravato’s approval, but he also saw the harms and costs of FDA-mandated oversight. Events like Perry’s death, he said, show that it is very potentially dangerous to allow patients access to this home.
Kaplin, now chief scientific officer of Mira Pharmaceuticals, is working to develop a derivative of ketamine with fewer side effects. According to him, the goal is to create a drug that even the FDA considers safe for patients at home.
#FDA #warning #death #Matthew #Perry #darken #glow #ketamines
Image Source : www.washingtonpost.com